These results indicate the high potential of ACP treatment to attenuate bacterial virulence within relatively short treatment times (60 s), which could prove valuable for future in vivo ACP applications targeting internal or indeed surface infections or as a mode of low toxicity pre-emptive infection control. The gene discussed is NDUFAB1; the disease is infection.